Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Receives Consensus Rating of “Hold” from Analysts

Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) has received an average rating of “Hold” from the eleven ratings firms that are currently covering the company, Marketbeat Ratings reports. Two investment analysts have rated the stock with a sell recommendation, three have given a hold recommendation, five have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price target among brokers that have covered the stock in the last year is $18.25.

Several analysts recently weighed in on the company. Truist Financial set a $8.00 price objective on Bicycle Therapeutics in a report on Tuesday. Morgan Stanley reiterated a “sell” rating and set a $13.00 target price on shares of Bicycle Therapeutics in a report on Tuesday. Weiss Ratings reissued a “sell (e+)” rating on shares of Bicycle Therapeutics in a research report on Monday, December 22nd. Finally, Jefferies Financial Group upgraded shares of Bicycle Therapeutics to a “strong-buy” rating in a report on Tuesday, February 17th.

Insider Buying and Selling

In related news, CEO Kevin Lee sold 10,989 shares of the business’s stock in a transaction that occurred on Monday, January 5th. The shares were sold at an average price of $6.46, for a total value of $70,988.94. Following the completion of the transaction, the chief executive officer owned 618,996 shares of the company’s stock, valued at $3,998,714.16. The trade was a 1.74% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO Alethia Young sold 4,334 shares of the stock in a transaction on Monday, January 5th. The shares were sold at an average price of $6.49, for a total value of $28,127.66. Following the sale, the chief financial officer directly owned 87,081 shares in the company, valued at $565,155.69. This trade represents a 4.74% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 38,029 shares of company stock valued at $251,966 in the last three months. 8.50% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Bicycle Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the stock. Fcpm Iii Services B.V. raised its holdings in Bicycle Therapeutics by 0.5% in the fourth quarter. Fcpm Iii Services B.V. now owns 3,468,430 shares of the company’s stock worth $24,556,000 after purchasing an additional 16,100 shares in the last quarter. Armistice Capital LLC boosted its holdings in shares of Bicycle Therapeutics by 8.7% in the 4th quarter. Armistice Capital LLC now owns 3,236,000 shares of the company’s stock valued at $22,911,000 after buying an additional 258,000 shares in the last quarter. Westfield Capital Management Co. LP grew its position in shares of Bicycle Therapeutics by 2.2% in the 4th quarter. Westfield Capital Management Co. LP now owns 3,016,026 shares of the company’s stock worth $21,353,000 after buying an additional 63,483 shares during the last quarter. GSK plc purchased a new position in shares of Bicycle Therapeutics in the 4th quarter worth approximately $10,829,000. Finally, Long Focus Capital Management LLC raised its stake in shares of Bicycle Therapeutics by 7.7% during the 3rd quarter. Long Focus Capital Management LLC now owns 1,418,695 shares of the company’s stock worth $10,981,000 after acquiring an additional 101,402 shares in the last quarter. Institutional investors own 86.15% of the company’s stock.

Bicycle Therapeutics Stock Up 0.4%

Shares of NASDAQ:BCYC opened at $5.07 on Wednesday. The business’s 50 day moving average is $5.91 and its 200 day moving average is $6.81. The stock has a market cap of $351.70 million, a P/E ratio of -1.40 and a beta of 1.65. Bicycle Therapeutics has a 52-week low of $4.77 and a 52-week high of $9.94.

Bicycle Therapeutics (NASDAQ:BCYC) last issued its earnings results on Tuesday, March 17th. The company reported ($0.29) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.00) by $0.71. Bicycle Therapeutics had a negative return on equity of 36.05% and a negative net margin of 884.51%.The business had revenue of $47.96 million during the quarter, compared to analyst estimates of $7.08 million. On average, sell-side analysts anticipate that Bicycle Therapeutics will post -3.06 EPS for the current fiscal year.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc is a clinical-stage biotechnology company specializing in the discovery and development of novel peptide therapeutics based on its proprietary bicyclic peptide platform. The company’s core technology leverages constrained peptide structures that combine the binding specificity of biologics with the favorable tissue-penetration properties of small molecules. This approach is designed to generate highly selective drug candidates with potential applications across a range of therapeutic areas, including oncology, neuroscience and immunology.

Bicycle Therapeutics maintains a diversified pipeline of internally developed programs as well as collaborations with leading pharmaceutical partners.